These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20118639)

  • 21. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
    Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
    Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular virology of hepatitis C].
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of alpha interferon on the hepatitis C virus replicon.
    Guo JT; Bichko VV; Seeger C
    J Virol; 2001 Sep; 75(18):8516-23. PubMed ID: 11507197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
    Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
    Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
    Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
    Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiviral agents for analyzing virus life cycle: chemical genetics for virology].
    Watashi K
    Yakugaku Zasshi; 2013; 133(11):1169-75. PubMed ID: 24189558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus entry.
    Zeisel MB; Felmlee DJ; Baumert TF
    Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.
    Poumbourios P; Drummer HE
    Antivir Chem Chemother; 2007; 18(4):169-89. PubMed ID: 17907376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.
    O'Boyle DR; Nower PT; Lemm JA; Valera L; Sun JH; Rigat K; Colonno R; Gao M
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1346-53. PubMed ID: 15793110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus.
    Zheng X; Guo R; Liu Q; Wakae K; Watanabe N; Fukano K; Que L; Li Y; Aly HH; Watashi K; Suzuki R; Murayama A; Kato T; Aizaki H; Wakita T; Huang X; Yan Y; Song SJ; Muramatsu M
    Biochem Biophys Res Commun; 2021 Aug; 567():1-8. PubMed ID: 34130179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
    Jarczak D; Korf M; Beger C; Manns MP; Krüger M
    FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
    Steinmann E; Whitfield T; Kallis S; Dwek RA; Zitzmann N; Pietschmann T; Bartenschlager R
    Hepatology; 2007 Aug; 46(2):330-8. PubMed ID: 17599777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture.
    Pietschmann T; Lohmann V; Kaul A; Krieger N; Rinck G; Rutter G; Strand D; Bartenschlager R
    J Virol; 2002 Apr; 76(8):4008-21. PubMed ID: 11907240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Form confers function: Case of the 3'X region of the hepatitis C virus genome.
    Dutkiewicz M; Ciesiołka J
    World J Gastroenterol; 2018 Aug; 24(30):3374-3383. PubMed ID: 30122877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future options for the management of hepatitis C.
    Davis GL; Nelson DR; Reyes GR
    Semin Liver Dis; 1999; 19 Suppl 1():103-12. PubMed ID: 10349698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.